The Amgen FIRST STEP™ Program is open to patients who meet the following criteria:
- An appropriate patient for Neulasta® (pegfilgrastim), Nplate®* (romiplostim), XGEVA® (denosumab), or Prolia®(denosumab) treatment.
- Currently have commercial health insurance that covers medication costs for Neulasta®, Nplate®, XGEVA®, or Prolia®(denosumab) under a medical benefit plan.
- Not a participant in Medicare, Medicaid, or another federally funded healthcare program.
- Not a resident of, or receiving treatment in, the State of Massachusetts
Ongoing eligibility in the Amgen FIRST STEP™ Program is contingent on submission of the required Explanation of Benefits form by the patient's healthcare provider’s office within 45 days of your treatment covered by the program. If a patient’s co-insurance or co-payment exceeds $1000 for an applicable dose, the balance in excess of $1000 will be applied to the Amgen FIRST STEP™ Program card once the patient’s EOB form is processed by the program. Once that form has been processed, office staff simply need to swipe the card at the patient’s next visit to receive payment for amounts due to the clinic/institution. There is no retroactive coverage available under this program. Any treatment prior to the patient’s enrollment date will be considered retroactive and therefore not eligible for Amgen FIRST STEP™ benefits.
Starting January 1 eligible patients must re-enroll in the program on an annual basis for benefit coverage of a single course of treatment. Eligible patients may re-enroll at any time a new course of treatment with a covered Amgen product is initiated.
Amgen reserves the right to modify or terminate this program, in whole or in part without notice at any time. The program is not valid where prohibited by law.
